01665nas a2200277   4500000000100000000000100001008004100002260001100043653001800054653003100072653003200103653002300135653003100158100001100189700001300200700001300213700002800226700001500254700001800269245009400287856004400381300000800425490000700433520093300440022001401373       2020                            d  c2020/910aAD biomarkers10aAlzheimer’s disease (AD)10aBlood–brain barrier (BBB)10amicrofluidic chips10athree-dimensional AD model1 aYan Li1 aDanni Li1 aPei Zhao1 aKrishnaswamy Nandakumar1 aLiqiu Wang1 aYouqiang Song00aMicrofluidics-Based Systems in Diagnosis of Alzheimer’s Disease and Biomimetic Modeling  uhttps://www.mdpi.com/2072-666X/11/9/787  a7870 v113 aEarly detection and accurate diagnosis of Alzheimer’s disease (AD) is essential for patient care and disease treatment. Microfluidic technology is emerging as an economical and versatile platform in disease detection and diagnosis. It can be conveniently integrated with nanotechnology and/or biological models for biomedical functional and pre-clinical treatment study. These strengths make it advantageous in disease biomarker detection and functional analysis against a wide range of biological backgrounds. This review highlights the recent developments and trends of microfluidic applications in AD research. The first part looks at the principles and methods for AD diagnostic biomarker detection and profiling. The second part discusses how microfluidic chips, especially organ-on-a-chip platforms, could be used as an independent approach and/or integrated with other technologies in AD biomimetic functional analysis.  a2072-666X